IMS Capital Management boosted its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 11.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,958 shares of the company’s stock after acquiring an additional 300 shares during the quarter. IMS Capital Management’s holdings in Zoetis were worth $543,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the stock. Webster Bank N. A. grew its holdings in Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares during the period. Quarry LP grew its position in Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Zoetis during the fourth quarter worth $40,000. LRI Investments LLC acquired a new stake in shares of Zoetis during the 1st quarter valued at about $43,000. Finally, Hazlett Burt & Watson Inc. lifted its stake in Zoetis by 60.7% in the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after acquiring an additional 102 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.
Zoetis Stock Up 0.3 %
Shares of NYSE ZTS opened at $195.38 on Tuesday. The business has a fifty day moving average of $186.33 and a two-hundred day moving average of $174.93. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The stock has a market cap of $88.52 billion, a PE ratio of 37.65, a PEG ratio of 2.99 and a beta of 0.88.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on ZTS. Stifel Nicolaus upped their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. BTIG Research increased their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $220.38.
Get Our Latest Research Report on ZTS
Zoetis Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Five stocks we like better than Zoetis
- Learn Technical Analysis Skills to Master the Stock Market
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Financial Services Stocks Investing
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.